EP2601175A1 — A novel crystalline compound comprising saxagliptin and phosphoric acid
Assigned to Sandoz AG · Expires 2013-06-12 · 13y expired
What this patent protects
The present invention refers to a crystalline compound comprising a mixture of a compound of formula (I) (INN: Saxagliptin) and phosphoric acid or a hydrate thereof, wherein the molar ratio of the compound of formula I and the phosphoric acid is in the range of from 1:0,8 to :1,2…
USPTO Abstract
The present invention refers to a crystalline compound comprising a mixture of a compound of formula (I) (INN: Saxagliptin) and phosphoric acid or a hydrate thereof, wherein the molar ratio of the compound of formula I and the phosphoric acid is in the range of from 1:0,8 to :1,2, as well as a process of obtaining the same.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.